Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both fir...

詳細記述

書誌詳細

主要な著者:	Miriam Blasi, Daniel Kazdal, Michael Thomas, Petros Christopoulos, Mark Kriegsmann, Regine Brandt, Anna-Lena Volckmar, Martina Kirchner, Claus Peter Heußel, Albrecht Stenzinger, Jonas Kuon
フォーマット:	Artigo
言語:	Inglês
出版事項:	Karger Publishers 2021-03-01
シリーズ:	Case Reports in Oncology
主題:	non-small cell lung cancer egfr mutation met amplification targeted therapy
オンライン･アクセス:	https://www.karger.com/Article/FullText/513904
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!